Uveitic Glaucoma Market Report and Forecast 2025-2034
Description
The uveitic glaucoma market was valued at USD 800.04 Million in 2024 driven by the increasing prevalence of the autoimmune disease among the 8 major markets. It is expected to grow at a CAGR of 6.70% during the forecast period of 2025-2034 and attain a market value of USD 1530.23 Million by 2034.
Uveitic Glaucoma Market Overview
Uveitic glaucoma is a complex ocular disorder characterized by increased intraocular pressure due to uveitis-inflammation of the uvea. The uveitic glaucoma treatment involves anti-inflammatory, immunosuppressive, and biologic therapies aimed at controlling inflammation and preventing long-term damage. The market growth is driven by the rise in autoimmune diseases and the effectiveness associated with early diagnosis.
Uveitic Glaucoma Market Growth Drivers
Rising Prevalence of Autoimmune Diseases Drives Market Growth
The National Health Council estimates that around 50 million Americans are affected by autoimmune diseases, with some studies indicating an annual rise of 3-12%, suggesting that autoimmunity is increasing in prevalence. The increase in the incidence of autoimmune diseases, such as rheumatoid arthritis and lupus, which are linked to secondary uveitic glaucoma, is driving demand for effective treatments.
Uveitic Glaucoma Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
Focus on Combination Therapies
One of the major market trends in the treatment of uveitic glaucoma involves the increasing incorporation of combination methods like corticosteroids, immunosuppressants, and biologics, offering a more holistic approach to symptom management. This approach has proven highly successful in complex cases, reducing the likelihood of recurrence, and improving overall patient outcomes.
Emphasis on Early Diagnosis to Boost Uveitic Glaucoma Market Value
The market growth is expected to be driven by the rising demand for early-stage treatment and the availability of timely intervention options. Improved screening methods and increased awareness are leading to early detection of uveitic glaucoma, thereby, enhancing treatment outcomes.
Shift Towards Targeted Therapies
In January 2024, Tarsier Pharma received FDA approval for its TRS01 eye drops under the Special Protocol Assessment (SPA). The approvals followed the results of the Tarsier-04 Phase 3 Trial. The protocol's goal was to assess the effectiveness of the medication in non-infectious uveitis and uveitic glaucoma. The SPA confirms the FDA's alignment with the trial's design, supporting its potential for future regulatory submission. This marks a pivotal movement towards targeted therapies, offering a steroid-free treatment option for inflammation, and addressing a critical unmet need in ocular disease management. Steroid-based therapies, traditionally used for treating uveitis and glaucoma, have side effects like increased intraocular pressure. The approval of TRS01 has led to a shift towards steroid-free targeted therapies, promising better patient outcomes and supporting the growth of safer, more effective treatment options in the forecast period.
Rising Utilization of Biologic to Meet Rising Uveitic Glaucoma Market Demand
Biologic medications are becoming more common in the treatment of uveitic glaucoma due to their unique mechanisms that improve treatment outcomes and reduce adverse reactions. Biologics are considered advanced treatment options as they target specific immune responses, resulting in more precise and effective symptom control.
Uveitic Glaucoma Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Segmentation Based on Treatment Holds a Significant Market Share
Based on the treatment, the market is segmented into anti-inflammatory, immunosuppressive, antibiotics, and others. Among these, anti-inflammatory treatments are expected to lead the market due to their critical role in managing the condition. Inflammation is the key feature of uveitic glaucoma, making corticosteroids and biologics the primary treatment options for the condition.
Uveitic Glaucoma Market by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market share in the forecast period due to a favorable regulatory environment that will result in more drug approvals. Furthermore, the market receives a significant boost from major healthcare and pharmaceutical companies in the region.
Leading Players in the Uveitic Glaucoma Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Pfizer Inc.
Based in New York, USA, Pfizer is a leading company in the pharmaceutical domain worldwide. The company has created medications such as Xeljanz (tofacitinib) for the treatment of uveitic glaucoma, a condition where autoimmune disorders can lead to eye inflammation.
Merck & Co. Inc.
Situated in Kenilworth, New Jersey, Merck provides treatments such as Keytruda (pembrolizumab) for inflammatory conditions. The company aims to develop drugs that address multiple issues like inflammation linked to uveitic glaucoma.
Teva Pharmaceutical Industries Ltd
Based in Petah Tikva, Israel, Teva offers a range of treatments for eye conditions, such as Copaxone (glatiramer acetate) for autoimmune disorder-associated uveitis. Although its primary focus is on multiple sclerosis, the drug's effect on ocular inflammation has also been studied in cases of uveitic glaucoma.
Bayer AG
Bayer, based in Leverkusen, Germany, is dedicated to developing groundbreaking treatments for eye ailments. Brolucizumab (Beovu), a biologic, is utilized for the treatment of uveitis-related retinal conditions. It works by reducing inflammation and intraocular pressure, which are critical in the management of uveitic glaucoma.
Other companies include Aerie Pharmaceuticals, Inc., Allergan Inc., Fera Pharmaceuticals, EyePoint Pharmaceuticals Inc., Amorphex Therapeutics Holdings, Inc., Kubota Vision Inc., Astellas Pharma Inc., and Bausch Health.
Key Questions Answered in the Uveitic Glaucoma Market
Uveitic Glaucoma Market Overview
Uveitic glaucoma is a complex ocular disorder characterized by increased intraocular pressure due to uveitis-inflammation of the uvea. The uveitic glaucoma treatment involves anti-inflammatory, immunosuppressive, and biologic therapies aimed at controlling inflammation and preventing long-term damage. The market growth is driven by the rise in autoimmune diseases and the effectiveness associated with early diagnosis.
Uveitic Glaucoma Market Growth Drivers
Rising Prevalence of Autoimmune Diseases Drives Market Growth
The National Health Council estimates that around 50 million Americans are affected by autoimmune diseases, with some studies indicating an annual rise of 3-12%, suggesting that autoimmunity is increasing in prevalence. The increase in the incidence of autoimmune diseases, such as rheumatoid arthritis and lupus, which are linked to secondary uveitic glaucoma, is driving demand for effective treatments.
Uveitic Glaucoma Market Trends
Several trends and developments are being observed in the market to enhance the current situation. The following are some of the noteworthy trends.
Focus on Combination Therapies
One of the major market trends in the treatment of uveitic glaucoma involves the increasing incorporation of combination methods like corticosteroids, immunosuppressants, and biologics, offering a more holistic approach to symptom management. This approach has proven highly successful in complex cases, reducing the likelihood of recurrence, and improving overall patient outcomes.
Emphasis on Early Diagnosis to Boost Uveitic Glaucoma Market Value
The market growth is expected to be driven by the rising demand for early-stage treatment and the availability of timely intervention options. Improved screening methods and increased awareness are leading to early detection of uveitic glaucoma, thereby, enhancing treatment outcomes.
Shift Towards Targeted Therapies
In January 2024, Tarsier Pharma received FDA approval for its TRS01 eye drops under the Special Protocol Assessment (SPA). The approvals followed the results of the Tarsier-04 Phase 3 Trial. The protocol's goal was to assess the effectiveness of the medication in non-infectious uveitis and uveitic glaucoma. The SPA confirms the FDA's alignment with the trial's design, supporting its potential for future regulatory submission. This marks a pivotal movement towards targeted therapies, offering a steroid-free treatment option for inflammation, and addressing a critical unmet need in ocular disease management. Steroid-based therapies, traditionally used for treating uveitis and glaucoma, have side effects like increased intraocular pressure. The approval of TRS01 has led to a shift towards steroid-free targeted therapies, promising better patient outcomes and supporting the growth of safer, more effective treatment options in the forecast period.
Rising Utilization of Biologic to Meet Rising Uveitic Glaucoma Market Demand
Biologic medications are becoming more common in the treatment of uveitic glaucoma due to their unique mechanisms that improve treatment outcomes and reduce adverse reactions. Biologics are considered advanced treatment options as they target specific immune responses, resulting in more precise and effective symptom control.
Uveitic Glaucoma Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Anterior Uveitis
- Intermediate Uveitis
- Posterior Uveitis
- Panuveitis
- Others
- Anti-inflammatory
- Antibiotics
- Immunosuppressive
- Others
- Oral
- Injectable
- Others
- Hospitals and Clinics
- Online Pharmacies
- Retail Pharmacies
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Market Segmentation Based on Treatment Holds a Significant Market Share
Based on the treatment, the market is segmented into anti-inflammatory, immunosuppressive, antibiotics, and others. Among these, anti-inflammatory treatments are expected to lead the market due to their critical role in managing the condition. Inflammation is the key feature of uveitic glaucoma, making corticosteroids and biologics the primary treatment options for the condition.
Uveitic Glaucoma Market by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and India. Among these, the United States is expected to lead the market share in the forecast period due to a favorable regulatory environment that will result in more drug approvals. Furthermore, the market receives a significant boost from major healthcare and pharmaceutical companies in the region.
Leading Players in the Uveitic Glaucoma Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Pfizer Inc.
Based in New York, USA, Pfizer is a leading company in the pharmaceutical domain worldwide. The company has created medications such as Xeljanz (tofacitinib) for the treatment of uveitic glaucoma, a condition where autoimmune disorders can lead to eye inflammation.
Merck & Co. Inc.
Situated in Kenilworth, New Jersey, Merck provides treatments such as Keytruda (pembrolizumab) for inflammatory conditions. The company aims to develop drugs that address multiple issues like inflammation linked to uveitic glaucoma.
Teva Pharmaceutical Industries Ltd
Based in Petah Tikva, Israel, Teva offers a range of treatments for eye conditions, such as Copaxone (glatiramer acetate) for autoimmune disorder-associated uveitis. Although its primary focus is on multiple sclerosis, the drug's effect on ocular inflammation has also been studied in cases of uveitic glaucoma.
Bayer AG
Bayer, based in Leverkusen, Germany, is dedicated to developing groundbreaking treatments for eye ailments. Brolucizumab (Beovu), a biologic, is utilized for the treatment of uveitis-related retinal conditions. It works by reducing inflammation and intraocular pressure, which are critical in the management of uveitic glaucoma.
Other companies include Aerie Pharmaceuticals, Inc., Allergan Inc., Fera Pharmaceuticals, EyePoint Pharmaceuticals Inc., Amorphex Therapeutics Holdings, Inc., Kubota Vision Inc., Astellas Pharma Inc., and Bausch Health.
Key Questions Answered in the Uveitic Glaucoma Market
- What was the uveitic glaucoma market value in 2024?
- What is the uveitic glaucoma market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the type?
- What is the market breakup based on the treatment?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on the distribution channel?
- What are the major factors aiding the uveitic glaucoma market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major uveitic glaucoma market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the uveitic glaucoma market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
- What are the key factors driving posterior uveitis treatment demand?
- How is anti-inflammatory treatment used in managing uveitic glaucoma?
- What role do injectable treatments play in uveitic glaucoma management?
- How is the growth of online pharmacies impacting the uveitic glaucoma market?
- How does the United States contribute to the uveitic glaucoma market?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Uveitic Glaucoma Market Overview – 8 Major Markets
- 3.1 Uveitic Glaucoma Market Historical Value (2018-2024)
- 3.2 Uveitic Glaucoma Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Uveitic Glaucoma Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Uveitic Glaucoma Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 Germany
- 7.2.4 France
- 7.2.5 Italy
- 7.2.6 Spain
- 7.2.7 India
- 7.2.8 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 Germany
- 7.3.4 France
- 7.3.5 Italy
- 7.3.6 Spain
- 7.3.7 India
- 7.3.8 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 Italy
- 7.4.6 Spain
- 7.4.7 India
- 7.4.8 Japan
- 8 Uveitic Glaucoma Market Landscape – 8 Major Markets
- 8.1 Uveitic Glaucoma Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Uveitic Glaucoma Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Route of Administration
- 9 Uveitic Glaucoma Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Uveitic Glaucoma Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Uveitic Glaucoma Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Uveitic Glaucoma Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Anterior Uveitis
- 12.1.3 Intermediate Uveitis
- 12.1.4 Posterior Uveitis
- 12.1.5 Panuveitis
- 12.1.6 Others
- 12.2 Uveitic Glaucoma Market (2018-2034) by Treatment
- 12.2.1 Market Overview
- 12.2.2 Anti-inflammatory
- 12.2.3 Antibiotics
- 12.2.4 Immunosuppressive
- 12.2.5 Others
- 12.3 Uveitic Glaucoma Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Injectable
- 12.3.4 Others
- 12.4 Uveitic Glaucoma Market (2018-2034) by Distribution Channel
- 12.4.1 Market Overview
- 12.4.2 Hospitals and Clinics
- 12.4.3 Online Pharmacies
- 12.4.4 Retail Pharmacies
- 12.4.5 Others
- 12.5 Uveitic Glaucoma Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 United Kingdom
- 12.5.4 Germany
- 12.5.5 France
- 12.5.6 Italy
- 12.5.7 Spain
- 12.5.8 Japan
- 12.5.9 India
- 13 United States Uveitic Glaucoma Market (218-2034)
- 13.1 United States Uveitic Glaucoma Market (2018-2034) by Type
- 13.1.1 Market Overview
- 13.1.2 Anterior Uveitis
- 13.1.3 Intermediate Uveitis
- 13.1.4 Posterior Uveitis
- 13.1.5 Panuveitis
- 13.1.6 Others
- 13.2 United States Uveitic Glaucoma Market (2018-2034) by Treatment
- 13.2.1 Market Overview
- 13.2.2 Anti-inflammatory
- 13.2.3 Antibiotics
- 13.2.4 Immunosuppressive
- 13.2.5 Others
- 13.3 United States Uveitic Glaucoma Market (2018-2034) by Route of Administration
- 13.3.1 Market Overview
- 13.3.2 Oral
- 13.3.3 Injectable
- 13.3.4 Others
- 13.4 United States Uveitic Glaucoma Market (2018-2034) by Distribution Channel
- 13.4.1 Market Overview
- 13.4.2 Hospitals and Clinics
- 13.4.3 Online Pharmacies
- 13.4.4 Retail Pharmacies
- 13.4.5 Others
- 14 United Kingdom Uveitic Glaucoma Market (218-2034)
- 14.1 United Kingdom Uveitic Glaucoma Market (2018-2034) by Type
- 14.1.1 Market Overview
- 14.1.2 Neuromodulation
- 14.1.3 Anticholinergics
- 14.1.4 Mirabegron
- 14.1.5 BOTOX
- 14.1.6 Others
- 14.2 United Kingdom Uveitic Glaucoma Market (2018-2034) by Disease Type
- 14.2.1 Market Overview
- 14.2.2 Idiopathic Overactive Bladder
- 14.2.3 Neurogenic Overactive Bladder
- 14.3 United Kingdom Uveitic Glaucoma Market (2018-2034) by Distribution Channel
- 14.3.1 Market Overview
- 14.3.2 Hospital Pharmacies
- 14.3.3 Retail Pharmacies
- 14.3.4 Online Pharmacies
- 15 Germany Uveitic Glaucoma Market (218-2034)
- 15.1 Germany Uveitic Glaucoma Market (2018-2034) by Type
- 15.1.1 Market Overview
- 15.1.2 Anterior Uveitis
- 15.1.3 Intermediate Uveitis
- 15.1.4 Posterior Uveitis
- 15.1.5 Panuveitis
- 15.1.6 Others
- 15.2 Germany Uveitic Glaucoma Market (2018-2034) by Treatment
- 15.2.1 Market Overview
- 15.2.2 Anti-inflammatory
- 15.2.3 Antibiotics
- 15.2.4 Immunosuppressive
- 15.2.5 Others
- 15.3 Germany Uveitic Glaucoma Market (2018-2034) by Route of Administration
- 15.3.1 Market Overview
- 15.3.2 Oral
- 15.3.3 Injectable
- 15.3.4 Others
- 15.4 Germany Uveitic Glaucoma Market (2018-2034) by Distribution Channel
- 15.4.1 Market Overview
- 15.4.2 Hospitals and Clinics
- 15.4.3 Online Pharmacies
- 15.4.4 Retail Pharmacies
- 15.4.5 Others
- 16 France Uveitic Glaucoma Market (218-2034)
- 16.1 France Uveitic Glaucoma Market (2018-2034) by Type
- 16.1.1 Market Overview
- 16.1.2 Anterior Uveitis
- 16.1.3 Intermediate Uveitis
- 16.1.4 Posterior Uveitis
- 16.1.5 Panuveitis
- 16.1.6 Others
- 16.2 France Uveitic Glaucoma Market (2018-2034) by Treatment
- 16.2.1 Market Overview
- 16.2.2 Anti-inflammatory
- 16.2.3 Antibiotics
- 16.2.4 Immunosuppressive
- 16.2.5 Others
- 16.3 France Uveitic Glaucoma Market (2018-2034) by Route of Administration
- 16.3.1 Market Overview
- 16.3.2 Oral
- 16.3.3 Injectable
- 16.3.4 Others
- 16.4 France Uveitic Glaucoma Market (2018-2034) by Distribution Channel
- 16.4.1 Market Overview
- 16.4.2 Hospitals and Clinics
- 16.4.3 Online Pharmacies
- 16.4.4 Retail Pharmacies
- 16.4.5 Others
- 17 Italy Uveitic Glaucoma Market (218-2034)
- 17.1 Italy Uveitic Glaucoma Market (2018-2034) by Type
- 17.1.1 Market Overview
- 17.1.2 Anterior Uveitis
- 17.1.3 Intermediate Uveitis
- 17.1.4 Posterior Uveitis
- 17.1.5 Panuveitis
- 17.1.6 Others
- 17.2 Italy Uveitic Glaucoma Market (2018-2034) by Treatment
- 17.2.1 Market Overview
- 17.2.2 Anti-inflammatory
- 17.2.3 Antibiotics
- 17.2.4 Immunosuppressive
- 17.2.5 Others
- 17.3 Italy Uveitic Glaucoma Market (2018-2034) by Route of Administration
- 17.3.1 Market Overview
- 17.3.2 Oral
- 17.3.3 Injectable
- 17.3.4 Others
- 17.4 Italy Uveitic Glaucoma Market (2018-2034) by Distribution Channel
- 17.4.1 Market Overview
- 17.4.2 Hospitals and Clinics
- 17.4.3 Online Pharmacies
- 17.4.4 Retail Pharmacies
- 17.4.5 Others
- 18 Spain Uveitic Glaucoma Market (218-2034)
- 18.1 Spain Uveitic Glaucoma Market (2018-2034) by Type
- 18.1.1 Market Overview
- 18.1.2 Anterior Uveitis
- 18.1.3 Intermediate Uveitis
- 18.1.4 Posterior Uveitis
- 18.1.5 Panuveitis
- 18.1.6 Others
- 18.2 Spain Uveitic Glaucoma Market (2018-2034) by Treatment
- 18.2.1 Market Overview
- 18.2.2 Anti-inflammatory
- 18.2.3 Antibiotics
- 18.2.4 Immunosuppressive
- 18.2.5 Others
- 18.3 Spain Uveitic Glaucoma Market (2018-2034) by Route of Administration
- 18.3.1 Market Overview
- 18.3.2 Oral
- 18.3.3 Injectable
- 18.3.4 Others
- 18.4 Spain Uveitic Glaucoma Market (2018-2034) by Distribution Channel
- 18.4.1 Market Overview
- 18.4.2 Hospitals and Clinics
- 18.4.3 Online Pharmacies
- 18.4.4 Retail Pharmacies
- 18.4.5 Others
- 19 Japan Uveitic Glaucoma Market (218-2034)
- 19.1 Japan Uveitic Glaucoma Market (2018-2034) by Type
- 19.1.1 Market Overview
- 19.1.2 Anterior Uveitis
- 19.1.3 Intermediate Uveitis
- 19.1.4 Posterior Uveitis
- 19.1.5 Panuveitis
- 19.1.6 Others
- 19.2 Japan Uveitic Glaucoma Market (2018-2034) by Treatment
- 19.2.1 Market Overview
- 19.2.2 Anti-inflammatory
- 19.2.3 Antibiotics
- 19.2.4 Immunosuppressive
- 19.2.5 Others
- 19.3 Japan Uveitic Glaucoma Market (2018-2034) by Route of Administration
- 19.3.1 Market Overview
- 19.3.2 Oral
- 19.3.3 Injectable
- 19.3.4 Others
- 19.4 Japan Uveitic Glaucoma Market (2018-2034) by Distribution Channel
- 19.4.1 Market Overview
- 19.4.2 Hospitals and Clinics
- 19.4.3 Online Pharmacies
- 19.4.4 Retail Pharmacies
- 19.4.5 Others
- 20 India Uveitic Glaucoma Market (218-2034)
- 20.1 India Uveitic Glaucoma Market (2018-2034) by Type
- 20.1.1 Market Overview
- 20.1.2 Anterior Uveitis
- 20.1.3 Intermediate Uveitis
- 20.1.4 Posterior Uveitis
- 20.1.5 Panuveitis
- 20.1.6 Others
- 20.2 India Uveitic Glaucoma Market (2018-2034) by Treatment
- 20.2.1 Market Overview
- 20.2.2 Anti-inflammatory
- 20.2.3 Antibiotics
- 20.2.4 Immunosuppressive
- 20.2.5 Others
- 20.3 India Uveitic Glaucoma Market (2018-2034) by Route of Administration
- 20.3.1 Market Overview
- 20.3.2 Oral
- 20.3.3 Injectable
- 20.3.4 Others
- 20.4 India Uveitic Glaucoma Market (2018-2034) by Distribution Channel
- 20.4.1 Market Overview
- 20.4.2 Hospitals and Clinics
- 20.4.3 Online Pharmacies
- 20.4.4 Retail Pharmacies
- 20.4.5 Others
- 21 Regulatory Framework
- 21.1 Regulatory Overview
- 21.2 US FDA
- 21.3 EU EMA
- 21.4 Japan PMDA
- 21.5 India CDSCO
- 21.6 Others
- 22 Patent Analysis
- 22.1 Analysis by Type of Patent
- 22.2 Analysis by Publication Year
- 22.3 Analysis by Issuing Authority
- 22.4 Analysis by Patent Age
- 22.5 Analysis by CPC Analysis
- 22.6 Analysis by Patent Valuation
- 23 Clinical Trials Analysis
- 23.1 Analysis by Trial Registration Year
- 23.2 Analysis by Trial Status
- 23.3 Analysis by Trial Phase
- 23.4 Analysis by Therapeutic Area
- 23.5 Analysis by Geography
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Drug Class of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Drug Class of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share Analysis, By Region (Top 5 Companies)
- 27.2 Aerie Pharmaceuticals, Inc.
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Companies News and Developments
- 27.2.5 Certifications
- 27.3 Allergan Inc.
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Companies News and Developments
- 27.3.5 Certifications
- 27.4 Bausch Health
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Companies News and Developments
- 27.4.5 Certifications
- 27.5 Merck & Co. Inc.
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Companies News and Developments
- 27.5.5 Certifications
- 27.6 Pfizer Inc
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Companies News and Developments
- 27.6.5 Certifications
- 27.7 Fera Pharmaceuticals
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Companies News and Developments
- 27.7.5 Certifications
- 27.8 Teva Pharmaceutical Industries Ltd
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Companies News and Developments
- 27.8.5 Certifications
- 27.9 EyePoint Pharmaceuticals Inc.
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Companies News and Developments
- 27.9.5 Certifications
- 27.10 Amorphex Therapeutics Holdings, Inc.
- 27.10.1 Financial Analysis
- 27.10.2 Product Portfolio
- 27.10.3 Demographic Reach and Achievements
- 27.10.4 Companies News and Developments
- 27.10.5 Certifications
- 27.11 Kubota Vision Inc
- 27.11.1 Financial Analysis
- 27.11.2 Product Portfolio
- 27.11.3 Demographic Reach and Achievements
- 27.11.4 Companies News and Developments
- 27.11.5 Certifications
- 27.12 Bayer AG
- 27.12.1 Financial Analysis
- 27.12.2 Product Portfolio
- 27.12.3 Demographic Reach and Achievements
- 27.12.4 Companies News and Developments
- 27.12.5 Certifications
- 27.13 Astellas Pharma Inc.
- 27.13.1 Financial Analysis
- 27.13.2 Product Portfolio
- 27.13.3 Demographic Reach and Achievements
- 27.13.4 Companies News and Developments
- 27.13.5 Certifications
- 28 Uveitic Glaucoma Market - Distribution Model (Additional Insight)
- 28.1 Overview
- 28.2 Potential Distributors
- 28.3 Key Parameters for Distribution Partner Assessment
- 29 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 30 Payment Methods (Additional Insight)
- 30.1 Government Funded
- 30.2 Private Insurance
- 30.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
